Conflict of interest declaration: Richard W Orrell

Roles in: Neuromuscular Group

1. In the past three years have you accepted the following from an organisation that may gain or lose financially from the publication of reviews by your review group in the Cochrane Database of Systematic Reviews (CDSR)?

a) Reimbursement for attending a conference or symposium (including travel, accommodation and/or hospitality)?
No

b) Fees for speaking?
No

c) Fees for organising education?
No

d) Funds for research?
Yes - Alnylam Pharmaceuticals: APOLLO: a phase 3 multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Patisiran (ALN-TTR02) in transthyretin (TTR)-mediated polyneuropathy (familial amyloidotic polyneuropathy-FAP). Coinvestigator. 2015- ISIS Pharmaceuticals: A phase 3 open-label extension study to assess the long-term safety and efficacy of ISIS 420915 in patients with familial amyloid polyneuropathy (FAP). Coinvestigator. 2015-

e) Funds for a member of staff?
No

f) Fees for consulting?
Yes - Chair of Data and Safety Monitoring Committee. Effects of ODM-109 on Respiratory Function in patients with ALS. Orion Pharmaceuticals. (2015- 2017)

g) Royalty payments?
No

2. In the past three years have you or your spouse/partner been employed by an organization that may in any way gain or lose financially from the publication of reviews by your review group in the CDSR?
No

3. Do you own stocks or shares in companies that may gain or lose financially from the publication of reviews by your review group in the CDSR?
No

4. Do you hold any patents for products that that may lead you to gain or lose financially from the publication of reviews by your review group in the CDSR?
No

5. Do you have any other competing interests (financial or non-financial)?
No